Keyphrases
Netherlands
100%
Dutch
94%
Cost-effectiveness Analysis
47%
Older Adults
43%
Cost-effectiveness
41%
Vaccination
40%
Quadrivalent
37%
Influenza Vaccination
33%
Respiratory Syncytial Virus
25%
Health Councils
24%
Quality-adjusted Life Years
23%
National Immunization Program
21%
Hospitalization
18%
Quadrivalent Influenza Vaccine
15%
Pneumococcal Vaccination
15%
Conjugate Vaccine
15%
Prevention Programs
15%
Influenza Prevention
15%
Trivalent Influenza Vaccine
15%
Trivalent
15%
United Kingdom
15%
Cardiovascular Hospitalizations
15%
Vaccination Policy
15%
Capacity Shortage
15%
Health Economics
15%
Respiratory Hospitalization
15%
Economic Perspective
15%
Respiratory Infection
15%
High-dose Influenza Vaccine
15%
High Dose
15%
Emerging Focus
15%
Cost-of-illness Analysis
15%
Hospital Capacity
15%
Respiratory Syncytial Virus Vaccines
15%
Infectious Diseases
15%
Invasive Pneumococcal Disease
15%
Neisseria Meningitidis Serogroup B
15%
XBB.1.5
15%
BNT162b2
15%
COVID-19
15%
MRNA-1273
15%
Nirsevimab
15%
Lower Respiratory Tract Infection
15%
Infant Protection
15%
Willingness-to-pay Threshold
15%
Vaccine Price
15%
Societal Perspective
13%
Sensitivity Analysis
13%
MenB
13%
Influenza
11%
Medicine and Dentistry
Health Care Cost
65%
Cost-Effectiveness Analysis
63%
Influenza Vaccination
33%
Drug Megadose
33%
Influenza Vaccine
31%
Quality Adjusted Life Year
22%
Cardiovascular System
17%
Infection
15%
Cost of Illness
15%
Respiratory Tract Infection
15%
Meningococcal Disease
15%
Neisseria meningitidis
15%
COVID-19
15%
Messenger RNA
15%
Public Health
13%
Sequela
10%
Polysaccharide
10%
Health Technology
7%
Randomized Controlled Trial
7%
Technology Assessment
7%
Cardiorespiratory
7%
Lifespan
5%
Pneumococcus Vaccine
5%
Polysaccharide Vaccine
5%
